Founded based on an unusual idea for combating multiresistant pathogens, Altermune Technologies LLC is getting a business makeover, inking a joint venture deal with Loxbridge Research LLP that brings the biotech $7 million in seed funding and allows the firm's scientists to focus on advancing the technology. Read More
LONDON – An antibody to a component of the complement cascade may have the potential to provide a new treatment for bacterial meningitis – if the company that manufactures it will release enough of it to allow large-scale trials to take place. Read More
Vical Inc., of Bethesda, Md., reported animal data demonstrating synergistic improvement in efficacy using a combination of the company's Allovectin immunotherapy with an anti-CTLA-4 antibody in a melanoma animal model. Read More
Advanced Cell Technology Inc., of Marlborough, Mass., has received clearance from the UK Medicines and Healthcare products Regulatory Agency to treat patients as part of a Phase I/II trial for Stargardt's macular dystrophy (SMD) using retinal pigment epithelium (RPE) derived from human embryonic stem cells. Read More
PharmAthene Inc. scored a stunning victory in its five-year legal battle against SIGA Technologies Inc., with the Delaware Court of Chancery awarding PharmAthene half of the net profits from SIGA's smallpox drug ST-246, subject of a government contract worth up to $2.8 billion. Read More
Ambrx Inc. became the latest jewel in the string of pearls that Bristol-Myers Squibb Co. is assembling, landing a deal worth $24 million up front for pegylated versions of the fibroblast growth factor 21 (FGF-21) protein and the relaxin hormone. Read More
